Comparative Pharmacology
Head-to-head clinical analysis: LYBALVI versus ZIPRASIDONE MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYBALVI versus ZIPRASIDONE MESYLATE.
LYBALVI vs ZIPRASIDONE MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYBALVI is a combination of olanzapine and samidorphan. Olanzapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and 5-HT2C, dopamine D1-D4, histamine H1, and alpha1-adrenergic receptors. Samidorphan is an opioid receptor antagonist with high affinity for mu-opioid receptors, hypothesized to reduce olanzapine-associated weight gain by blocking opioid receptors in the central nervous system.
Ziprasidone mesylate is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also antagonizes 5-HT1D, 5-HT2C, and alpha1-adrenergic receptors, and inhibits serotonin and norepinephrine reuptake.
Olanzapine 10 mg / samidorphan 10 mg orally once daily.
20 mg intramuscularly (IM) as needed, not to exceed 40 mg/day; oral: 20 mg twice daily with food, titrated up to 80 mg twice daily. Maximum: 160 mg/day oral.
None Documented
None Documented
Terminal half-life ~20-30 hours; supports once-daily dosing.
Terminal elimination half-life is approximately 2.2 hours (range 1.4–3.6 h) for the mesylate salt; clinical context: requires twice-daily dosing.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40%; Biliary: minor.
Approximately 20% renal, 80% fecal/biliary. Unchanged drug accounts for <1% of renal excretion.
Category C
Category A/B
Atypical Antipsychotic
Atypical Antipsychotic